Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Cash from Financing Activities (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Cash from Financing Activities for 2 consecutive years, with $223000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Financing Activities rose 49.66% year-over-year to $223000.0, compared with a TTM value of $8.4 million through Jun 2025, changed N/A, and an annual FY2024 reading of $5.1 million, up 1308.0% over the prior year.
  • Cash from Financing Activities was $223000.0 for Q2 2025 at Kairos Pharma, down from $3.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.2 million in Q3 2024 and bottomed at -$142000.0 in Q4 2024.